Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT06374745
Recruiting Observational

An Integrated Algorithm for Surgical Intervention in Chronic Lymphedema After Breast Cancer Treatment: The Basel Lymphedema Protocol

NCT06374745 · tracked via the Priya Life Science Switzerland tracker
Sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Started
2015-01-02
Last updated
2025-02-10

Condition(s) studied

LymphedemaBreast Cancer

Study summary

The primary objective of the investigators is to develop an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. This will be achieved by retrospectively analysing a subgroup of patients who had breast cancer-related surgery prior to lymphedema.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * status post breast cancer or status post another type of cancer or status post no cancer * chronic lymphedema - lymphedema lasting over three months - present prior to surgical treatment * one type of surgical procedure for treatment of chronic lymphedema or a combination of surgical procedures for treatment of chronic lymphedema was performed * one or any combination of the following surgical procedures was used in each individual patient: Lymph Node-Vein Anastomosis (LNVA) , Lymphaticovenous Anastomosis (LVA), Tumescent Liposuction (TL), Vascularized Lymph Node Transfer (VLNT) and/or Water-Assisted Liposuction (WAL) Exclusion Criteria: * inclusion criteria not met * loss to follow-up (data not successfully collected)

Primary outcome measure(s)

  • To design an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. — baseline to follow up (no later than December 2024)
    To design an integrated algorithm for surgical treatment of chronic cancer-associated lymphedema using the following variables captured in Primary Outcomes 2 to 21.
  • Date of follow-up procedure — baseline to follow up (no later than December 2024)
    Date of follow-up procedure.
  • Follow-up and type of lymphedema surgery — baseline to follow up (no later than December 2024)
    If applicable, follow-up and type of lymphedema surgery
  • Circumferences of the affected and unaffected side — baseline to follow up (no later than December 2024)
    Circumferences of the affected and unaffected side preoperatively and at postoperative time points.
  • Postoperative complications — baseline to follow up (no later than December 2024)
    Postoperative complications
  • Surgery duration. — baseline to follow up (no later than December 2024)
    Surgery duration in minutes.
  • Type of lymphedema surgery — baseline to follow up (no later than December 2024)
    Type of lymphedema surgery including number of anastomoses, localization, long-term patency.
  • Date of lymphedema surgery — baseline to follow up (no later than December 2024)
    Date of lymphedema surgery.
  • Use of compression stockings — baseline to follow up (no later than December 2024)
    Use of compression stockings
  • Number of lymphedema drainages per week — baseline to follow up (no later than December 2024)
    Number of lymphedema drainages per week.
  • Stage of lymphedema — baseline to follow up (no later than December 2024)
    Stage of lymphedema (stage I, II or III)
  • Duration of lymphedema — baseline to follow up (no later than December 2024)
    Duration of lymphedema.
  • Location of lymphedema — baseline to follow up (no later than December 2024)
    Location of lymphedema.
  • Subsequent cancer treatment — baseline to follow up (no later than December 2024)
    Subsequent cancer treatment (Chemotherapy, Radiotherapy)
  • Date of cancer related surgery — baseline to follow up (no later than December 2024)
    Date of cancer related surgery
  • Tumor staging — baseline to follow up (no later than December 2024)
    Tumor staging, considering the following parameters: tumor node metastasis (TNM), resection status of the cancerous growth (R), lymphatic vessel invasion by cancerous cells (L), venous invasion by cancerous cells (V) and grade of cancer cells (G).
  • Tumor location — baseline to follow up (no later than December 2024)
    Tumor location (right, left, both sides).
  • BMI — baseline to follow up (no later than December 2024)
    Patient's BMI in kg/m2.
  • Comorbidities — baseline to follow up (no later than December 2024)
    Existence of comorbidities.
  • Age — baseline to follow up (no later than December 2024)
    Patient's age in years.
  • Gender — baseline to follow up (no later than December 2024)
    Patient's gender, given the possibilities male or female.

Trial sites (1)

FacilityCityRegionStatus
University Hospital Basel Basel Switzerland Recruiting

More University Hospital, Basel, Switzerland trials in Switzerland

Enhancement of Stroke Rehabilitation With Levodopa Active, not recruiting
Characteristics of Patients in the ICU With Palliative Care Consults in a Tertiary University Hospital Active, not recruiting
Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI) Active, not recruiting
Lymphatic Injury Visualization in Vascular Surgery Starting soon
Basics in Acute Shortness of Breath EvaLuation (BASEL V) Study Active, not recruiting

Other trials for the same condition

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Recruiting
Stress Reduction Through Acupuncture Recruiting
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery Recruiting
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions Recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06374745 on ClinicalTrials.gov ↗ ← All trials in Switzerland